Actionable news
All posts from Actionable news
Actionable news in BIIB: Biogen Idec Inc.,

Jim Cramer: Biogen (BIIB) 'Does Not Fit the Allergan Bill'

NEW YORK (TheStreet) -- Biogen (BIIB - Get Report) stock closed up by 5.25% to $279.57 on Wednesday, due to expectations that Allergan (AGN) will pursue new acquisitions after its deal with Pfizer (PFE) was terminated.

The biopharmaceutical company's stock climbed today due to speculation that the company could be acquired by Allergan, TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer wrote in an article today.

However, acquiring Biogen may not be a "sensible" decision for Allergan, he said.

Back by Popular Demand…“Confessions of a Street Addict” Get a FREE signed copy of Jim Cramer’s national best-seller when you gain access to his multi-million dollar charitable trust portfolio! Click here to see Jim’s holdings and get your FREE...